



US 20210393788A1

(19) **United States**(12) **Patent Application Publication**
Speyer(10) **Pub. No.: US 2021/0393788 A1**(43) **Pub. Date: Dec. 23, 2021**(54) **IGA FC-FOLATE CONJUGATES,
PHARMACEUTICAL COMPOSITIONS AND
METHODS TO TREAT CANCER**continuation of application No. 15/227,747, filed on
Aug. 3, 2016, now Pat. No. 10,286,080.(60) Provisional application No. 62/200,463, filed on Aug.
3, 2015.(71) Applicant: **Wayne State University**, Detroit, MI
(US)(72) Inventor: **Cecilia Speyer**, Novi, MI (US)(73) Assignee: **Wayne State University**, Detroit, MI
(US)(21) Appl. No.: **17/466,922**(22) Filed: **Sep. 3, 2021****Related U.S. Application Data**(63) Continuation of application No. 16/409,575, filed on
May 10, 2019, now Pat. No. 11,135,302, which is a**Publication Classification**(51) **Int. Cl.**
A61K 47/68 (2006.01)**A61K 47/55** (2006.01)(52) **U.S. Cl.**
CPC **A61K 47/68** (2017.08); **A61K 47/551**
(2017.08)(57) **ABSTRACT**IgA-based Fc-folate conjugates as a treatment for cancer are
provided. The conjugates utilize only the Fc portion of IgA
to target its receptor on neutrophils (Fc α R1) to elicit anti-
body-dependent cellular-cytotoxicity (ADCC).